Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Radnai, Balazs ^a   Antus, Csenge ^a   Racz, Boglarka ^a   Engelmann, Peter ^a   Priber, Janos K ^a   Tucsek, Zsuzsanna ^a   Veres, Balazs ^a   Turi, Zsuzsanna ^a   Lorand, Tamas ^a   Sumegi, Balazs ^a,b,c   Gallyas Jr, Ferenc ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

c Jun N terminal kinase (JNK); Mitochondrial depolarization; Mitogen activated protein kinase (MAPK); Poly(ADP ribose) polymerase (PARP); Protein kinase B (PKB Akt)

Indexed keywords

2,4 DIMETHOXYPHENYL 4 ARYLIDENE 3 ISOCHROMANONE; ACETYLCYSTEINE; CYTOTOXIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE 9; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL DEATH; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MEMBRANE DEPOLARIZATION; WOUND HEALING;

ACETYLCYSTEINE; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 9; NECROSIS; PHENANTHRENES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84860819343     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-34     Document Type: Article

References (31)

1. Oliveira NG, Castro M, Rodrigues AS, Goncalves IC, Martins C, Toscano Rico JM, Rueff J. Effect of poly(ADP-ribosyl)ation inhibitors on the genotoxic effects of the boron neutron capture reaction. Mutat Res 2005, 583:36-48. 10.1016/j.mrgentox.2005.01.015, 15866464.
2. De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2006, 2:179-185. 1483123, 16810332.
3. Bowman KJ, Newell DR, Calvert AH, Curtin NJ. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 2001, 84:106-112. 10.1054/bjoc.2000.1555, 2363607, 11139322.
4. Virag L, Szabo C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54:375-429. 10.1124/pr.54.3.375, 12223530.
5. Veres B, Gallyas F, Varbiro G, Berente Z, Osz E, Szekeres G, Szabo C, Sumegi B. Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock. Biochem Pharmacol 2003, 65(8):1373-1382. 10.1016/S0006-2952(03)00077-7, 12694878.
6. Szanto A, Bognar Z, Szigeti A, Szabo A, Farkas L, Gallyas F. Critical Role of Bad Phosphorylation by Akt in Cytostatic Resistance of Human Bladder Cancer Cells. Anticancer Res 2009, 29:159-164.
7. Szanto A, Hellebrand EE, Bognar Z, Tucsek Z, Szabo A, Gallyas F, Sumegi B, Varbiro G. PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol. Biochem Pharmacol 2009, 77(8):1348-1357. 10.1016/j.bcp.2009.01.008, 19426673.
8. Mester L, Szabo A, Atlasz T, Szabadfi K, Reglodi D, Kiss P, Racz B, Tamas A, Gallyas F, Sumegi B, Hocsak E, Gabriel R, Kovacs K. Protection Against Chronic Hypoperfusion-Induced Retinal Neurodegeneration by PARP Inhibition via Activation of PI-3-kinase Akt Pathway and Suppression of JNK and p38 MAP Kinases. Neurotox Res 2009, 16(1):68-76. 10.1007/s12640-009-9049-6, 19526300.
9. Abdallah Y, Gligorievski D, Kasseckert SA, Dieterich L, Schäfer M, Kuhlmann CR, Noll T, Sauer H, Piper HM, Schäfer C. The role of poly(ADP-ribose) polymerase (PARP) in the autonomous proliferative response of endothelial cells to hypoxia. Cardiovasc Res 2007, 1(3):568-574. 73.
10. Lee S, Yoon S, Kim DH. A high nuclear basal level of ERK2 phosphorylation contributes to the resistance of cisplatin-resistant human ovarian cancer cells. Gynecol Oncol 2007, 104(2):338-344. 10.1016/j.ygyno.2006.08.040, 17023032.
11. Clark JS, Faisal A, Baliga R, Nagamine Y, Arany I. Cisplatin induces apoptosis through the ERK-p66shc pathway in renal proximal tubule cells. Cancer Lett 2010, 28(2):165-170. 297.
12. Chen YJ, Liu WH, Kao PH, Wang JJ, Chang LS. Involvement of p38 MAPK- and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon 2010, 55(7):1306-1316. 10.1016/j.toxicon.2010.01.024, 20144638.
13. Racz B, Hanto K, Tapodi A, Solti I, Kalman N, Jakus P, Kovacs K, Debreceni B, Gallyas F, Sumegi B. Regulation of MKP-1 expression and MAPK activation by PARP-1 in oxidative stress: A new mechanism for cytoplasmic effect of PARP-1 activation. Free Radic Biol Med 2010, 49(12):1978-1988. 10.1016/j.freeradbiomed.2010.09.026, 20920579.
14. Tapodi A, Debreceni B, Hanto K, Bognar Z, Wittmann I, Gallyas F, Varbiro G, Sumegi B. Pivotal role of Akt activation in mitochondrial protection and cell survival by poly(ADP-ribose)polymerase-1 inhibition in oxidative stress. J Biol Chem 2005, 280(42):35767-35775. 10.1074/jbc.M507075200, 16115861.
15. Lemasters JJ, Nieminen AL, Qian T, Trost LC, Elmore SP, Nishimura Y, Crowe RA, Cascio WE, Bradham CA, Brenner DA, Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim Biophys Acta 1998, 1366:177-196. 10.1016/S0005-2728(98)00112-1, 9714796.
16. Leber B, Geng F, Kale J, Andrews DW. Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med 2010, 12:e28.
17. Szigeti A, Bellyei S, Gasz B, Boronkai A, Hocsak E, Minik O, Bognar Z, Varbiro G, Sumegi B, Gallyas F. Induction of necrotic cell death and mitochondrial permeabilization by heme binding protein 2/SOUL. FEBS Lett 2006, 580(27):6447-6454. 10.1016/j.febslet.2006.10.067, 17098234.
18. Rasola A, Sciacovelli M, Chiara F, Pantic B, Brusilow WS, Bernardi P. Activation of mitochondrial ERK protects cancer cells from death through inhibition of the permeability transition. Proc Natl Acad Sci U S A 2010, 107(2):726-731. 10.1073/pnas.0912742107, 2818893, 20080742.
19. Huszar M, Varga A, Horvath A, Lorand T, Agocs A, Idei M, Mandl J, Vantus T, Keri G. Comparative characterization of experimental and calculated lipophilicity and anti-tumour activity of isochromanone derivatives. Curr Med Chem 2010, 17(4):321-333. 10.2174/092986710790192703, 20015044.
20. Lorand T, Forgo P, Foldesi A, Osz E, Prokai L. Improved solvent-free synthesis and structure elucidation of (E)- and (Z)-4-arylmethylene-3-isochromanones. Eur J Org Chem 2002, 17:2996-3003.
21. Kalai T, Balog M, Szabo A, Gulyas G, Jeko J, Sumegi B, Hideg K. New poly(ADP-ribose) polymerase-1 inhibitors with antioxidant activity based on 4-carboxamidobenzimidazole-2-ylpyrroline and -tetrahydropyridine nitroxides and their precursors. J Med Chem 2009, 52(6):1619-1629. 10.1021/jm801476y, 19245212.
22. Palfi A, Toth A, Kulcsar G, Hanto K, Deres P, Bartha E, Halmosi R, Szabados E, Czopf L, Kalai T, Hideg K, Sumegi B, Toth K. The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly-(ADP-ribose)-polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts. J Pharmacol Exp Ther 2005, 315(1):273-282. 10.1124/jpet.105.088336, 15951400.
23. Grimm S, Brdiczka D. The permeability transition pores in cell death. Apoptosis 2007, 12(5):841-855. 10.1007/s10495-007-0747-3, 17453156.
24. Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, Szabados E, Kálai T, Hideg K, Halmosi R, Sumegi B, Toth K. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res 2009, 83(3):501-510. 10.1093/cvr/cvp144, 19443425.
25. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005, 52(1):109-118. 10.1016/j.phrs.2005.02.013, 15911339.
26. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275:90-94. 10.1126/science.275.5296.90, 8974401.
27. Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, Izumo S. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002, 277:10244-10250. 10.1074/jbc.M112355200, 11786558.
28. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Schöll C, Tothova Z, Attar EC, Fröhling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT. AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell 2011, 146(5):697-708. 10.1016/j.cell.2011.07.032, 21884932.
29. Wang S, Wang H, Davis BC, Liang J, Cui R, Chen SJ, Xu ZX. PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1. Biochem Biophys Res Commun 2011, 412(2):379-384. 10.1016/j.bbrc.2011.07.107, 3163691, 21821012.
30. Kaul R, Saha P, Saradhi M, Prasad LA, Chatterjee S, Ghosh I, Tyagi RK, Datta K. Overexpression of hyaluronan binding protein 1 (HABP1/p32/gC1qR) in HepG2 cell leads to increased hyaluronan synthesis and cell proliferation by upregulation of cyclin D1 in AKT-dependent pathway. J Biol Chem 2012, [Epub ahead of print].
31. Pan J, Chang Q, Wang X, Son Y, Zhang Z, Chen G, Luo J, Bi Y, Chen F, Shi X. Reactive oxygen species-activated Akt/ASK1/p38 signaling pathway in nickel compound-induced apoptosis in BEAS 2B cells. Chem Res Toxicol 2010, 23(3):568-77. 10.1021/tx9003193, 2838407, 20112989.